Lupin Limited said it has received U.S. approval for Diazepam Injection, USP, marking a new regulatory clearance for the pharmaceutical company in the American market. The announcement was issued on July 28, 2026, from Mumbai, India, and Naples, Florida.
According to the company, the product was approved in the United States under the Federal Food, Drug, and Cosmetic Act. The update indicates that Lupin has secured authorization to offer Diazepam Injection, USP in the country, adding another approved medicine to its U.S. lineup.
The news is significant for Lupin because the United States remains a key market for global drugmakers, especially for approved generic and hospital-use products. An approval for an injectable medicine can strengthen a company's portfolio and expand its presence across healthcare channels.
While the company’s statement focused on the regulatory milestone, the approval also underscores Lupin’s continued activity in the U.S. pharmaceuticals sector. More commercial details are expected to come from the company as it outlines next steps for Diazepam Injection, USP in the United States.
